ANIX

Anixa Biosciences, Inc.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Anixa Biosciences, Inc. (ANIX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D+). The rating has held at C for 11 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C+
Factor Score 2.5 / 5.0
Momentum
C
Factor Score 2.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -8.2
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -25.7%
Price Return 12M -41.9%
Catalyst Signal 0.00
Market Cap $88.6M
TTM Revenue N/A
Price / Sales N/A
ROE -73.2%

Historical Factor Score Progression

Held C for 11 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) D+ (1.8) C+ (2.5) C (2.3) C+ (2.6) C (2.3)
2026-11-10 C+ (2.5) D+ (1.8) C+ (2.5) C+ (2.7) C+ (2.6) C (2.4)
2026-11-03 C+ (2.5) D+ (1.7) C+ (2.5) C+ (2.5) C+ (2.7) C (2.4)
2026-10-27 C+ (2.5) D+ (1.8) C+ (2.5) C- (2.1) C+ (2.6) C (2.3)
2026-10-20 C+ (2.5) D+ (1.7) C+ (2.5) C- (1.9) C+ (2.6) C (2.3)
Page 1 of 4